[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
[3] |
WANG Shuan, HUANG Can, QI Lamei.
Establishment and Evaluation of Apatinib-Induced Hypertension Prediction Model Based on Real-World Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 429-435.
|
[4] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[5] |
LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui.
Developments and Prospects of Radiopharmaceuticals in China
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
|
[6] |
SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng.
Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
|
[7] |
WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng.
Evaluation of drug safety with multicenter real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
|
[8] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[9] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[10] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[11] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|
[12] |
SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong.
Thoughts on constructing vigilance system of Chinese medical device in the new era
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
|
[13] |
TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei.
Progress in the application of real-world data in post-market surveillance of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
|
[14] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[15] |
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana.
Introduction and inspiration of international medical device regulators forum patient registry guidelines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
|